NSW Cannabis Medicines Advisory Service, Newcastle, New South Wales, Australia.
Australian Centre for Cannabinoid Clinical and Research Excellence, Newcastle, New South Wales, Australia.
Intern Med J. 2022 Feb;52(2):228-237. doi: 10.1111/imj.15635. Epub 2022 Feb 10.
In 2018, an innovative, State government-funded cannabis medicines drug information service was established for health professionals in New South Wales (NSW). The NSW Cannabis Medicines Advisory Service (CMAS) provides expert clinical guidance and support to medical practitioners considering prescribing a cannabis medicine to their patient(s).
This research examines quality assurance and patient outcomes related to enquirers' experience with NSW CMAS.
Data collection involved an online, anonymous survey with two components. Following a health professional enquiry, quality assurance data were collected about the enquirers' experience with NSW CMAS. The second survey focussed on patient outcomes and provides real-world observational data about cannabis medicines safety and effectiveness across a wide range of indications.
Data collection occurred between January 2020 and June 2021. Preliminary analyses were based on 68 quality assurance and 50 patient outcomes survey responses. General practitioners represented the highest proportion of survey responses (n = 33; 49%). The most common enquiry involved 'patient-specific advice' (n = 50; 74%). Patient-specific information provided by the service was mainly used for prescribing decision support (n = 45; 90%).
Preliminary findings highlight the impact of an innovative cannabis medicines drug information service in supporting health professional clinical practice in an area of rapid knowledge translation. Quality assurance data indicate that the service is perceived well by the majority of enquirers. Patient outcomes data across a wide range of indications suggest some effectiveness and a reasonable safety profile for prescribed cannabis medicines for most patients.
2018 年，新南威尔士州（新州）为卫生专业人员设立了一个创新性的、由州政府资助的大麻药物信息服务。新州大麻药物咨询服务（CMAS）为考虑为其患者开大麻药物的医疗从业者提供专业的临床指导和支持。
本研究考察了与 CMAS 咨询者体验相关的质量保证和患者结果。
数据收集涉及在线匿名调查，分为两个部分。在医疗专业人员咨询后，收集关于咨询者使用新州 CMAS 体验的质量保证数据。第二份调查侧重于患者结果，并提供关于大麻药物在广泛适应症范围内的安全性和有效性的真实世界观察数据。
数据收集于 2020 年 1 月至 2021 年 6 月进行。初步分析基于 68 份质量保证和 50 份患者结果调查回复。全科医生在调查回复中占比最高（n = 33；49%）。最常见的咨询涉及“患者具体建议”（n = 50；74%）。该服务提供的患者具体信息主要用于支持处方决策（n = 45；90%）。
初步研究结果突显了创新性大麻药物信息服务在支持医疗专业人员在快速知识转化领域的临床实践方面的影响。质量保证数据表明，该服务得到了大多数咨询者的认可。在广泛的适应症范围内的患者结果数据表明，对于大多数患者，所开处方的大麻药物具有一定的疗效和合理的安全性。
